© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
IGBA Panelists Discuss the Global Reputation of Biosimilars, Generics
Skylar Jeremias
February 21 2023
Panelists at the annual meeting of the International Generic and Biosimilar Medicines Association (IGBA) offered insight into the current state of the global biosimilar and generic markets and why government agencies need to leverage these medicines to address challenges in the pharmaceutical space.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
Skylar Jeremias
February 19 2023
COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Access 2023: Panelists Weigh In on the Many Factors Influencing Biosimilar Uptake Patterns
Skylar Jeremias
February 16 2023
Two presentations and a panel discussion at the annual meeting of the Association for Accessible Medicines (Access 2023) went over the current state of biosimilar uptake and the factors that help determine whether a biosimilar will experience good adoption rates.
Access 2023: Mark Cuban Teases Adding Biosimilars to Online Pharmacy, Champions Generics
Skylar Jeremias
February 15 2023
At the annual meeting of the Association for Accessible Medicines (Access 2023), Shark Tank’s Mark Cuban explained his dedication to and the inner workings of his online pharmacy that provides generic drugs to patients for significantly lower prices than traditional pharmacies.
What Will Be the Major Drivers Behind IQVIA's Predicted Biosimilars Uptake, Savings?
Skylar Jeremias
February 14 2023
Adalimumab and ustekinumab biosimilars aren't the only factors that will drive biosimilar adoption and savings through 2023, according to Michael Kleinrock, lead research director for the IQVIA Institute for Human Data Science.
Dr Michael Chiang: How the National Eye Institute Is Building Confidence in Ophthalmology Biosimilars
Skylar Jeremias
January 15 2023
AAO: American Academy of Ophthalmology
Michael Chiang, MD, director of the National Eye Institute, discusses how his team is working to instill greater confidence in ophthalmology biosimilars among wary ophthalmologists.
AAO Posters Investigate Ranibizumab Biosimilar Impact on Patient Outcomes
Skylar Jeremias
November 2 2022
AAO: American Academy of Ophthalmology
Two studies presented at the American Academy of Ophthalmology (AAO) annual meeting in Chicago, Illinois, demonstrated the impact that a ranibizumab biosimilar (SB11; Byooviz) can have on patient outcomes.
Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts
Skylar Jeremias
September 23 2022
Realigning definitions and policies across regulatory agencies and developing a better understanding of how different stakeholders approach biosimilars could help get more patients and providers on board with using biosimilars, according to panelists at the DIA Biosimilars Conference.